ICICI Prudential Pharma Healthcare & Diagnostics Growth Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹5,000

ICICI Prudential Pharma Healthcare & Diagnostics Growth Direct Plan

NAV
₹41.6200
-0.57%
(20 Dec)
AUM
5,024 Cr
TER
1.09%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
Asset Under Management (AUM) is in the top 25% of comparable funds
Total Expense Ratio (TER) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+50.4%
+34.0%
+33.2%
+32.7%
+20.7%
3Y
+27.0%
+36.3%
+35.8%
+37.7%
+35.8%
5Y
+31.5%
+29.7%
+31.7%
+26.2%
NA
ALL
+24.8%
+17.8%
+18.1%
+12.5%
+28.6%
VOL
15.2%
19.6%
18.1%
20.3%
22.7%
TER
1.1%
0.8%
1.2%
0.7%
0.5%
AUM
₹5,024 Cr
₹1,345 Cr
₹6,779 Cr
₹4,686 Cr
₹5,456 Cr
INFO
1.63
0.91
1.00
0.62
1.26
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
ICICI Pru Pharma Healthcare & Diagnostics (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Oct
Top holdings
Sun Pharmaceuticals Industries Ltd
14.4%
Dr Reddy's Laboratories Ltd
9.0%
Cipla Ltd
8.1%
Lupin Ltd
4.6%
Aurobindo Pharma Ltd
4.6%
Gland Pharma Ltd
4.2%
Apollo Hospitals Enterprise Ltd
3.8%
Treps
3.1%
Zydus Lifesciences Ltd
2.9%
Divi's Laboratories Ltd
2.7%
Top industry exposure
Healthcare
95.7%
Basic Materials
1.3%
Financial Services
0.9%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹5,000
Additional lumpsum
₹1,000
Portfolio turnover
91%
Lock-in period
-
Exit load
• 1% for redemption within 15 days
Fund objective
To generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. However there can be no assurance or guarantee that the investment objectives of the scheme would be achieved.
Fund manager(s)
Dharmesh Kakkad
Sharmila D’mello

FAQs